Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 61Carcinoma, Renal Cell 39Neoplasm Metastasis 38Neoplasms 24Kidney Neoplasms 20Neuroendocrine Tumors 19Recurrence 16Prostatic Neoplasms 15Head and Neck Neoplasms 13Tuberous Sclerosis 12Triple Negative Breast Neoplasms 12Lymphoma, Mantle-Cell 11Hodgkin Disease 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma 10Colorectal Neoplasms 10Waldenstrom Macroglobulinemia 9Stomach Neoplasms 9Multiple Myeloma 9Leukemia, Lymphocytic, Chronic, B-Cell 9Glioma 9Glioblastoma 9Brain Neoplasms 9Sarcoma 8Pancreatic Neoplasms 8Melanoma 8Lymphoma, Follicular 8Lung Neoplasms 8Endometrial Neoplasms 8

Interventions

Gemcitabine 15Doxorubicin 8Docetaxel 8Radiotherapy 7Trabectedin 6Nivolumab 5pazopanib 4liposomal doxorubicin 3Sunitinib 3Dacarbazine 3pembrolizumab 2eribulin 2durvalumab 2avelumab 2Specimen Handling 2Radiation Dose Hypofractionation 2Letrozole 2Ifosfamide 2Bevacizumab 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1temsirolimus 1sotigalimab 1selinexor 1sargramostim 1rucaparib 1ribociclib 1regorafenib 1pegfilgrastim 1olaratumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leiomyosarcoma × Everolimus × Clear all
NCT03114527 2026-05-22

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

Fox Chase Cancer Center

Phase 2 Active not recruiting
48 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡